{"disease":{"id":"myelodysplastic-syndromes-mds","name":"myelodysplastic syndromes mds"},"drugs":{"marketed":[{"drug_id":"cedazuridine","indication_name":"Myelodysplastic Syndromes (MDS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEDAZURIDINE","company_name":"","drug_phase":"marketed","molecular_target":"DNA methyltransferase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":45,"revenue":null,"mechanism":"Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation and cellular differentiation or apoptosis."},{"drug_id":"imetelstat","indication_name":"low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rytelo","generic_name":"IMETELSTAT","company_name":"Geron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02775383","title":"The National Myelodysplastic Syndromes (MDS) Study","phase":"","overall_status":"COMPLETED","enrollment_count":2115,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT07465029","title":"A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04064060","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":665,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT07355478","title":"Asia Myelodysplastic Syndrome (MDS) Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06971185","title":"A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07319793","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT00528983","title":"Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04997811","title":"Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Prof. Janet Dunn","has_results":false},{"nct_id":"NCT04202003","title":"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04275518","title":"A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT05092451","title":"Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01736683","title":"Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06886425","title":"Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT02966782","title":"A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02333058","title":"Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"medac GmbH","has_results":false},{"nct_id":"NCT03849651","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT01660607","title":"Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT07238712","title":"Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT06764511","title":"Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT05884333","title":"Cord Blood Transplant in Adults With Blood Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04326764","title":"Panobinostat Maintenance After HSCT fo High-risk AML and MDS","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Goethe University","has_results":false},{"nct_id":"NCT06465953","title":"Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03072498","title":"Collection of Samples From Patients With MDS","phase":"","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"PersImmune, Inc","has_results":false},{"nct_id":"NCT03593915","title":"A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":true},{"nct_id":"NCT06765876","title":"CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Institute of Hematology and Blood Transfusion, Czech Republic","has_results":false},{"nct_id":"NCT05709093","title":"A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT05048498","title":"Pharmacokinetics, Tolerability and Safety of NEX-18a","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Nanexa AB","has_results":false},{"nct_id":"NCT06581055","title":"A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04985656","title":"A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Takeda","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}